[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Thai vaccine heart complications", "description": "Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents\n\nhttps://www.preprints.org/manuscript/202208.0151/v1\n\nStudy focuses on cardiovascular effects, \n\nparticularly myocarditis and pericarditis events, \n\nafter BNT162b2 mRNA COVID-19 vaccine injection,\n\nin Thai adolescents, 13 to 18, both sexes \n\nThis prospective cohort study,\n\nstudents from two schools aged 13\u201318 years,\n\nwho received the second dose of the BNT162b2 vaccine. \n\nAll healthy and without any abnormal symptoms before receiving the second dose of vaccine. \n\nData collected\n\nDemographics\n\nSymptoms\n\nVital signs\n\nECG, echocardiography\n\nCardiac enzymes\n\nCollected \n\nat baseline, Day 3, Day 7, and Day 14\n\nN =  314\n\nAnalysis, n = 301\n\nCardiovascular effects\n\nFound in 29.24% of patients,\n\nranging from tachycardia, palpitation, and myopericarditis. \n\nMost common cardiovascular effects\n\nTachycardia, 7.64%\n\nShortness of breath, 6.64%\n\nPalpitation, 4.32%\n\nChest pain, 4.32%\n\nHypertension, 3.99%\n\nAbnormal ECG finding, 54 patients (17.94%) \n\nSeven participants (2.33%)\n\n(all male)\n\nAt least one elevated cardiac biomarker or positive lab assessments\n\nMyopericarditis\n\nConfirmed in one patient after vaccination. \n\nTwo patients had suspected pericarditis\n\nFour patients had suspected subclinical myocarditis \n\nThree patients had minimal pericardial effusion \n\nMyocarditis and Sudden Cardiac Death in the Young\n\nhttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.693085\n\nMyocarditis accounts for up to 20% of sudden cardiac deaths in young adults. \n\nDuring the follow-up period, (14 days)\n\nAfter receiving the second dose of vaccine, \n\ntwo patients were hospitalized,\n\none patient was supervised in the ICU during hospitalization, \n\n(mainly for observation of arrhythmia).\n\nConclusion\n\nThe clinical presentation of myopericarditis after vaccination was usually mild, with all cases fully recovering within 14 days. \n\nHence, adolescents receiving mRNA vaccines should be monitored for side effects. \n\nClinical Trial Registration: NCT05288231\n\nIncidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review\n\nhttps://www.bmj.com/content/378/bmj-2021-069445\n\nMale adolescents and male young adults are at the highest risk of myocarditis after an mRNA vaccination.\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html\n\nVaccines for COVID-19\n\nCOVID-19 vaccines are safe, effective, and free.\n\nCOVID-19 Vaccines for Children and Teens\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html\n\nCDC recommends covid -19 vaccines for everyone 6 months and older and boosters for everyone 5 years and older,", "link": "https://www.youtube.com/watch?v=ekTR0w2M9-U", "date_published": "2022-08-16 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]